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Introduction: Prior cross-sectional studies suggest that health-related quality of life (HRQOL) worsens with
more severe glomerular disease. This longitudinal analysis was conducted to assess changes in HRQOL
with changing disease status.
Methods: Cure Glomerulonephropathy (CureGN) is a cohort of patients with minimal change disease, focal
segmental glomerulosclerosis, membranous nephropathy, IgA vasculitis, or IgA nephropathy. HRQOL was
assessed at enrollment and follow-up visits 1 to 3 times annually for up to 5 years with the Patient-Reported
Outcomes Measurement Information System (PROMIS). Global health, anxiety, and fatigue domains were
measured in all; mobility was measured in children; and sleep-related impairment was measured in adults.
Linear mixed effects models were used to evaluate HRQOL responsiveness to changes in disease status.
Results: A total of 469 children and 1146 adults with PROMIS scores were included in the analysis. HRQOL
improved over time in nearly all domains, though group-level changes were modest. Edema was most
consistently associated with worse HRQOL across domains among children and adults. A greater number of
symptoms also predicted worse HRQOL in all domains. Sex, age, obesity, and serum albumin were associated
with some HRQOL domains. The estimated glomerular ﬁltration rate (eGFR) was only associated with fatigue
and adult physical health; proteinuria was not associated with any HRQOL domain in adjusted models.
Conclusion: HRQOL measures were responsive to changes in disease activity, as indicated by edema.
HRQOL over time was not predicted by laboratory-based markers of disease. Patient-reported edema and
number of symptoms were the strongest predictors of HRQOL, highlighting the importance of the patient
experience in glomerular disease. HRQOL outcomes inform understanding of the patient experience for
children and adults with glomerular diseases.
Kidney Int Rep (2020) 5, 1679–1689; https://doi.org/10.1016/j.ekir.2020.06.041
KEYWORDS: edema; health-related quality of life; patient-reported outcomes; primary glomerular disease
ª 2020 Published by Elsevier, Inc., on behalf of the International Society of Nephrology. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Correspondence: Shannon L. Murphy, University of North Carolina Kidney Center, 7024 Burnett-Womack / CB # 7155, Chapel
Hill, North Carolina 27599, USA. E-mail: shannon.murphy@
unchealth.unc.edu
Kidney International Reports (2020) 5, 1679–1689

18

Members of the CureGN (Cure Glomerulonephropathy) Consortium are listed in the Appendix.
Received 4 September 2019; revised 27 April 2020; accepted 9
June 2020; published online 23 July 2020
1679

CLINICAL RESEARCH

SL Murphy et al.: Longitudinal Changes in HRQOL in Primary Glomerula

gA nephropathy (IgAN), focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN),
and minimal change disease (MCD) are primary
glomerular diseases that have severe and lasting impacts on affected individuals. In both children and
adults, these diseases frequently cause chronic kidney
disease and can lead to end-stage kidney disease.1 Traditional laboratory measures of kidney function and
related disorders (e.g., serum creatinine or proteinuria)
are important for clinical management but fail to fully
capture the patient experience. Understanding the substantial and far-reaching impact of the experience of
glomerular diseases is essential to improving HRQOL.
Patient-reported outcomes (PROs), including
HRQOL, are increasingly recognized as a priority by
agencies such as the National Institutes of Health and
the Food and Drug Administration.2,3 PRO assessment
is essential for incorporating patient perspectives into
clinical decision making and research, while providing
a more complete and meaningful understanding of the
experience of glomerular diseases.
Glomerular diseases (IgAN, FSGS, MN, and MCD)
frequently cause nephrotic syndrome leading to edema,
hyperlipidemia, and complications such as venous
thromboembolic disease.4,5 Management of these
glomerular diseases includes immunosuppressive therapy (IST), which is associated with additional risks and
side effects. Patients with nephrotic syndrome have
been reported to experience poor HRQOL, on par with
dialysis patients.6,7 However, there have been few
studies describing HRQOL in this population, especially
adults. Further, these studies have mostly reported only
cross-sectional HRQOL without longitudinal follow-up.
The Cure Glomerulonephropathy (CureGN) study is
a multicenter longitudinal cohort study following
children and adults with IgAN, FSGS, MN, and MCD.
The objectives of the current study are (1) to describe
longitudinal patterns of HRQOL in patients with these
primary glomerular diseases and (2) to evaluate how
disease activity affects HRQOL over time.

I

METHODS
Patients
The CureGN study recruits children and adults with a
diagnostic kidney biopsy within the last 5 years
showing MCD, FSGS, MN, or IgAN (including IgA
vasculitis [IgAV]) from 67 sites across the United States,
as well as 2 sites in Canada, 1 in Italy, and 1 in Poland
(https://curegn.org). Approximately 600 patients each
of MCD, FSGS, and MN and 650 patients with IgAN or
IgAV will be enrolled. Patients are ineligible if they
have end-stage kidney disease or any of the following
before ﬁrst kidney biopsy: solid organ or bone marrow
1680

transplant, active HIV infection, hepatitis B or C
infection, diabetes mellitus, systemic lupus erythematosus, or active malignancy. Each participating site
obtained approval from an institutional review board,
and all patients and/or legal guardians of children gave
informed consent and, where age appropriate,
informed assent prior to enrollment in the study.8
In the current study, we present longitudinal data
from all enrolled patients in CureGN with PRO data
available at enrollment and follow-up up to September
5, 2018. Study details, including data collected, frequency of collection, and relationship to diagnostic
biopsy have been reported previously by Mariani
et al.8 Data from the September 5, 2018 CureGN Standard Analysis File were used for this analysis.
HRQOL Data
HRQOL was assessed at enrollment and follow-up using
measures selected from PROMIS.9 Each PROMIS measure generates a T score (mean ¼ 50, SD ¼ 10; normed to
the calibration population) where a higher score indicates higher levels of the trait being measured (i.e.,
higher mobility score ¼ better mobility; higher anxiety
score ¼ worse anxiety). We considered a minimally
important difference (MID) in outcomes an absolute
change of 3 units, which is likely a conservative estimate
based on available literature.10 Each question uses a
common time frame of “.the past 7 days,” and responses use a 5-item Likert-type scale from “never” to
“almost always” for the majority of domains. PROMIS
was administered as a paper form using a ﬁxed number
of items. These items were chosen a priori during the
design of the CureGN study by a working group of
clinician investigators, with the aim of measuring domains broadly relevant to patients with glomerular
disease while balancing the time burden on study participants. Questionnaires were available in French,
Spanish, Italian, and Polish. PROMIS domains have been
validated in Spanish,11 and translations for other languages were by native speakers to ensure that the intent
of the question remained the same.
Pediatric domains included global assessment of health
(7-item short form), mobility (4-item custom form), fatigue
(10-item short form), and anxiety (single item custom
form). Adult domains included: global assessment of
physical health (5-item short form), global assessment of
mental health (5-item short form), sleep-related impairments (single-item custom form), fatigue (7-item custom
form), and anxiety (single-item custom form).
For fatigue and anxiety, pediatric and adult measures were combined for pooled analyses. Pediatric
scores were converted to adult scales using linking
parameters. For both domains, average linking parameters of disabilities and special health care needs
Kidney International Reports (2020) 5, 1679–1689
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cohorts were used, and child scores were converted to
the adult scale.12,13 The remaining age-speciﬁc domains
(child global health, child mobility, adult physical and
mental health, and adult sleep impairments) were
analyzed in age-speciﬁc strata. A total of 7 PRO measures were analyzed.
Statistical Analysis
Categorical variables were described using frequencies
and percentages, and continuous variables using medians and interquartile ranges. To facilitate comparison
and understanding, PROMIS domains were transformed so that higher scores indicate better HRQOL.
The analysis sample was limited to patients with PRO
assessments at baseline and at least 1 follow-up visit.
Linear mixed effects models with subject-speciﬁc
slopes and intercepts were used to test for a signiﬁcant
temporal change in each score over time. These models
were repeated by domain with domain score as the
outcome and time, in units of days since baseline, as the
sole predictor. Functional form was explored by testing
polynomial terms for time (e.g., time2, time3). Longitudinal predictors of HRQOL were also assessed using
linear mixed effects models. A list of putative predictors
was generated including variables that were thought to
potentially affect HRQOL based on clinical expertise and
review of literature. The following time-ﬁxed and timevarying covariates were tested for main effects on
HRQOL: age, sex, race, disease duration, socioeconomic
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status (SES; measured by $college education in adults
and $maternal college education in children), diagnosis,
any edema, number of symptoms (patient-reported),
health care utilization (hospitalizations/emergency
department visits in the past 4 months), obesity status
(BMI >30 in adults; BMI >95th percentile in children),
short stature (measured by height <2.5th percentile in
children and height <152 cm in adult females or <164
cm in adult males), number of comorbidities, log urine
protein–creatinine ratio, eGFR (measured by modiﬁed
CKiD formula in children and CKD-EPI in adults),14,15
serum albumin, hemoglobin, IST exposure, steroid
dose in the past 30 days, steroid response pattern
(responsive, relapsing, resistant, or not treated), number
of medications, and patient-reported medication adherence. Interaction terms were used to test for differences
in changes in HRQOL over time in the following baseline covariates: age at enrollment, sex, race, disease
duration at enrollment, SES, and diagnosis.
Each covariate was tested as an unadjusted predictor
of each HRQOL domain. Any unadjusted association
with HRQOL at P <0.20 entered a multivariable
backward selection model. Variables were removed in
order of descending P value until all remaining variables were statistically signiﬁcant at p <0.05. Components of signiﬁcant interactions were retained to ensure
all models were hierarchically formulated. Multivariable models were adjusted for time. There were no
imputations for missing data.

Figure 1. CONSORT ﬂow diagram of included patients. Data as of September 5, 2018. *Could provide more than 1 reason. PRO, patient-reported
outcomes.
Kidney International Reports (2020) 5, 1679–1689
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Sensitivity analyses examined the relationship in
between-visit changes in edema status and betweenvisit changes in HRQOL using linear mixed effects
models with the outcome of change in HRQOL score
since last visit and the predictor of change in edema
status coded categorically as resolution of edema
(edema to no edema), persistence of edema (edema to
edema), onset of edema (no edema to edema), and no
edema (no edema to no edema).
RESULTS
A STROBE ﬂow diagram of included patients from
CureGN is displayed in Figure 1. These analyses are
based on 469 children (1795 observations) and 1146
adults (4764 observations) with longitudinal HRQOL
data. Characteristics of included versus excluded
patients $8 years of age (i.e., eligible for PROMIS selfreport) are compared in Table S1. CureGN patients
without longitudinal HRQOL data were more likely to
be older, less likely to be Hispanic, and more likely to
have IgA. The characteristics of included patients are
shown in Table 1 stratiﬁed by age. At enrollment, the
majority of patients had more than 1 year of follow-up

since diagnosis (median of 14 months in children; 17
months in adults). Samples were well represented by
diagnosis. Most frequent diagnoses among children
were MCD (32%) and FSGS (24%), and among adults
were MN (29%) and IgAN (28%). Children were less
likely than adults to present with edema at enrollment
(34% of children vs. 60% of adults); they also presented with lower urine protein–creatinine ratio (median 0.5 vs. 1.6 g/g) and higher eGFR (median 97 vs. 70
ml/min per 1.73 m2).
HRQOL Changes Over Time
Results of tests for temporal changes in HRQOL domains over time are presented in Figure 2. All domains
were associated with a signiﬁcant improvement over
time, with the exception of mental health in adults. No
models show signiﬁcant relationships with time
squared or cubed, and hence only linear effects are
shown. Among children, the largest improvement over
time was fatigue (mean ¼ þ1.6 points/yr) and the
smallest was anxiety (mean ¼ þ0.5 points/yr). Among
adults, the greatest improvement was seen in fatigue
(þ1.0 point/yr).

Table 1. Descriptive characteristics of included patients with baseline and at least 1 follow-up HRQOL assessment
Characteristic
Age at enrollment, median (IQR)
Female, n (%)

Overall (N[1615 patients;
N[6559 observations)
34 (16–52)
708 (44)

Children (n [ 469 patients;
n [ 1795 observations)
13 (10–15)

Adults (n [ 1146 patients;
n [ 4764 observations)
45 (32–58)

203 (43)

505 (44)
169 (15)

Race, n (%)
Black/African American
White/Caucasian
Other
Hispanic ethnicity, n (%)

260 (16)

91 (19)

1089 (67)

304 (65)

785 (68)

266 (16)

74 (16)

192 (17)

49 (10)

147 (13)

196 (12)

Duration of disease at enrollment, median (IQR)

16 (5–40)

15 (4–43)

16 (5–39)

Months of follow-up, median (IQR)

16 (7–27)

14 (6–25)

17 (8–28)

4 (2–5)

3 (2–5)

4 (2–5)

Number of PROMIS assessments, median (IQR)
Diagnosis, n (%)
MCD

306 (19)

150 (32)

FSGS

399 (25)

113 (24)

286 (25)

MN

363 (22)

28 (6)

335 (29)

IgAV

122 (8)

71 (15)

51 (4)

IgAN

425 (26)

107 (23)

318 (28)

Edema at enrollment, n (%)

843 (52)

161 (34)

682 (60)

UP-C at enrollment (g/g), median (IQR)

1.2 (0.3–3.7)

0.5 (0.1–1.9)

1.6 (0.4–4.2)

<0.3, n (%)

363 (22)

173 (37)

190 (17)

0.3–0.9, n (%)

268 (17)

90 (19)

178 (16)

1.0–3.5, n (%)

361 (22)

73 (16)

288 (25)

$3.5, n (%)

350 (22)

74 (16)

276 (24)

Missing, n (%)

273 (17)

59 (13)

214 (19)

eGFR at enrollment (ml/min per 1.73 m2), median (IQR)

80 (50–104)

97 (82–115)

156 (14)

70 (43–97)

$90, n (%)

601 (37)

275 (59)

326 (28)

60–89, n (%)

401 (25)

118 (25)

283 (25)

30–59, n (%)

346 (21)

27 (6)

319 (28)

<30, n (%)

144 (9)

12 (3)

132 (12)

Missing, n (%)

123 (8)

37 (8)

86 (8)

eGFR, estimated glomerular ﬁltration rate; FSGS, focal segmental glomerular sclerosis; IgAN, IgA nephropathy; IgAV, IgA vasculitis; IQR, interquartile range; MCD, minimal change
disease; MN, membranous nephropathy; PROMIS, Patient-Reported Outcomes Measurement Information System; UP-C, urine protein–creatinine ratio.
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Figure 2. Change in health-related quality of life (HRQOL) over time: results of linear mixed effects models by measure. Fatigue and anxiety are
linked to be on the same scale for children and adults. (a) *95% conﬁdence intervals are shown as dashed lines. (b) Due to the overlapping
estimates, conﬁdence intervals were suppressed to aid visualization. Patient-Reported Outcomes Measurement Information System (PROMIS)
scores were rescored so that higher numbers reﬂect better HRQOL.

Among children, 36% reported that their illness had
an effect on their education: 2% had left school, 3%
had repeated a grade, 6% had changed schools, and
30% reported impaired attendance. Of those reporting
missing school, participants reported missing a median
of 1 (IQR ¼ 0.5–2.5) day per month. Among adults,
11% had reported missing work or school, a median of
1 day per month (IQR ¼ 0.5–3.5 days).
Predictors of HRQOL Over Time
Results of unadjusted analyses are summarized in
Table S2. Sex, SES, edema, symptom burden, number
of comorbidities, health care utilization, weight,
Kidney International Reports (2020) 5, 1679–1689

proteinuria, serum albumin, and number of medications were signiﬁcant unadjusted predictors of each of
the HRQOL measures.
Final models for the combined child and adult
measures (fatigue and anxiety) are presented in Table 2.
Younger age, female sex, presence of edema, and more
symptoms were signiﬁcant predictors of both fatigue
and anxiety. Higher SES, higher eGFR, and greater
medication adherence were associated with less fatigue.
Obesity and greater number of medications were
associated with worse fatigue.
Results of ﬁnal models for the pediatric-speciﬁc domains (global health and mobility) are displayed in
1683
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Table 2. Final adjusted multivariable linear mixed effects models of
child and adult combined measures (N¼1615 patients; N¼6559
observations)
Measure

b (95% CI)

P

Child þ adult: fatigue
Age (per yr)
Male vs. female
SES (college education vs. none)

–0.12 (–0.15, –0.09)

<0.001

2.80 (1.74, 3.85)

<0.001

1.79 (0.73, 2.85)

0.001

Edema (any vs. none)

–2.93 (–3.59, –2.28)

<0.001

Number of symptoms (per symptom)

–0.87 (–1.09, –0.66)

<0.001

Underweight

0.58 (–1.84, 3.00)

0.64

Overweight

–1.17 (–2.10, –0.23)

0.01

Obese

–2.04 (–3.09, –0.99)

<0.001

Weight

Normal
eGFR (per 30 ml/min per 1.73 m2)

0.002

Ref
0.52 (0.13, 0.91)

0.01

Number of medications (per medication)

–0.26 (–0.38, –0.14)

<0.001

Exposed to CTX

–2.59 (–4.91, –0.27)

0.03

Time (per year)

1.01 (0.65, 1.37)

<0.001

–0.10 (–0.12, –0.09)

<0.001

2.00 (1.40, 2.61)

<0.001

Edema (any vs. none)

–1.71 (–2.11, –1.32)

<0.001

Number of symptoms (per symptom)

–0.40 (–0.53, –0.28)

<0.001

0.36 (0.16, 0.57)

<0.001

Child þ adult: anxiety
Age (per yr)
Male vs. female

Time (per yr)

CI, conﬁdence interval; CTX, Cytoxan (cyclophosphamide); eGFR, estimated glomerular
ﬁltration rate; Ref, referent; SES, socioeconomic status.
For each domain, scores have been transformed so higher scores indicate better
health-related quality of life.

Table 3. Edema, greater number of symptoms, obesity,
and lower serum albumin were signiﬁcant predictors of
worse global health and mobility. Female sex and
greater number of comorbidities predicted worse global
health, and more medications predicted worse
mobility.
Adult-speciﬁc ﬁnal models are shown in Table 4.
Edema, greater number of symptoms, and greater
number of comorbidities were signiﬁcant negative
predictors of all 3 adult measures. Diagnosis was associated with sleep and mental health but not physical
health; HRQOL scores were best in IgAV, followed by
MN, IgAN, FSGS, and MCD. Higher serum albumin
and fewer medications were associated with better
physical and mental health.
Changes in Disease Activity and HRQOL
We characterized disease activity primarily by edema
status, though proteinuria and albumin were also
evaluated as markers of disease activity. The multivariable models demonstrate that edema is consistently
associated with worse HRQOL. That is, patient visits
with edema have worse scores than those without
edema. Results of sensitivity analyses of visit-to-visit
changes in scores in response to changes in edema are
shown in Figure 3. Change in edema status was a signiﬁcant predictor of changes in all HRQOL domains.
For example, a child having resolution of edema, on
1684

average, experienced a 3.6-point improvement in
mobility, whereas a child with onset of edema had an
average 1.9-point decrease in mobility. Children whose
edema status remained the same showed either no
change or a minor improvement in mobility: 0.4-point
increase associated with persistent edema; 0.6-point
increase with no edema. As a reference, a minimally
important difference of 3.0 has been reported in children.10 Changes greater than 3 points are shown in
Table S3. For example, among those with resolution of
edema, 44% had a $3-point improvement in fatigue,
18% had a $3-point worsening, and the remaining
38% did not change by more than 3 points. This was
modestly different from those with onset of edema for
which 28% had a $3-point improvement in fatigue,
33% had a $3-point worsening, and the remaining
39% did not change by more than 3 points. These results show that children whose edema resolves between
visits (mean 4 months apart) improve above the minimally important difference for mobility and fatigue.
Similar trends were seen for adults, but changes
showed smaller effect sizes.
DISCUSSION
CureGN is the largest study to date to evaluate HRQOL
in patients with glomerular disease. By prospectively
Table 3. Final adjusted multivariable linear mixed effects models of
child measures (n ¼ 469 patients; n ¼ 1795 observations)
Measure

b (95% CI)

P

–0.44 (–0.69, –0.19)

<0.001

Child: Global
Age (per yr)
Male vs. female

2.11 (0.68, 3.55)

0.004

Edema (any vs. none)

–2.75 (–3.84, –1.66)

<0.001

Number of symptoms (per symptom)

–0.50 (–0.84, –0.16)

0.004

Number of comorbidities

–1.16 (–1.98, –0.34)

0.006
<0.001

Weight
Underweight

0.04 (–3.12, 3.24)

Overweight

–0.78 (–2.17, 0.62)

Obese

–4.00 (–5.46, –2.54)

Normal

Ref

Serum albumin (per g/dl)

1.37 (0.72, 2.03)

<0.001

Time (per yr)

0.37 (–0.37, 1.10)

0.33

Edema (any vs. none)

–3.13 (–4.17, –2.09)

<0.001

Number of symptoms (per symptom)

–0.72 (–1.04, –0.39)

<0.001

Child: Mobility

Weight

0.002

Underweight

1.50 (–1.51, 4.51)

Overweight

–0.58 (–1.85, 0.70)

Obese

–2.37 (–3.66, –1.08)

Normal

Ref

Serum albumin (per g/dl)

1.43 (0.81, 2.05)

Number of medications (per medication)
Time (per yr)

<0.001

–0.27 (–0.46, –0.07)

0.008

0.43 (–0.19, 1.05)

0.17

CI, conﬁdence interval; Ref, referent.
For each domain, scores have been transformed so higher scores indicate better
health-related quality of life.
Kidney International Reports (2020) 5, 1679–1689
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Table 4. Final adjusted multivariable linear mixed effects models of
adult measures (n ¼ 1146 patients; n ¼ 4764 observations)
b (95% CI)

P

Male vs. female

1.81 (0.94, 2.67)

<0.001

SES (college education vs. none)

2.13 (1.25, 3.00)

<0.001

Edema (any vs. none)

–3.16 (–3.72, –2.59)

<0.001

Number of symptoms (per symptom)

–1.02 (–1.20, –0.84)

<0.001

Number of comorbidities

–0.98 (–1.35, –0.61)

<0.001

Measure
Adult: Physical health

<0.001

Weight
Underweight

–0.02 (–3.02, 3.04)

Overweight

–0.89 (–1.69, –0.09)

Obese

–2.55 (–3.46, –1.64)

Normal

Ref

eGFR (per 30 ml/min per 1.73 m2)

0.89 (0.55, 1.24)

<0.001

Serum albumin (per g/dl)

0.94 (0.51, 1.37)

<0.001

Number of medications (per medication)

–0.27 (–0.36, –0.18)

<0.001

Exposed to steroids (yes vs. no)

–0.66 (–1.30, –0.01)

0.04

0.23 (–0.06, 0.52)

0.11

Time (per yr)
Adult: Sleep impairments
Diagnosis

0.004

MCD

–1.58 (–3.57, 0.42)

FSGS

–2.57 (–4.45, –0.69)

MN

–0.78 (–2.64, 1.08)

IgAN

–1.70 (–3.55, 0.16)

IgAV

Ref

Edema (any vs. none)

–2.05 (–2.52, –1.59)

<0.001

Number of symptoms (per symptom)

–0.59 (–0.75, –0.44)

<0.001

Number of comorbidities

–0.69 (–1.00, –0.39)

<0.001

Exposed to CTX (yes vs. no)

–2.62 (–4.20, –1.04)

0.001

Time since enrollment (per yr)

0.07 (–0.15, 0.29)

0.55

Adult: Mental health
<0.001

Diagnosis
MCD

–5.00 (–8.95, –1.08)

FSGS

–3.50 (–7.35, 0.34)

MN

–1.30 (–5.18, 2.58)

IgAN

–2.70 (–6.56, 1.15)

IgAV

Ref

Edema (any vs. none)

–1.28 (–2.13, –0.42)

0.003

Number of symptoms (per symptom)

–0.61 (–0.89, –0.32)

<0.001

Number of comorbidities

–1.44 (–1.97, –0.91)

<0.001

Serum albumin (per g/dl)

0.99 (0.34, 1.63)

0.003

–0.27 (–0.41, –0.13)

<0.001

Medication adherence (yes vs. no)

1.38 (0.63, 2.13)

<0.001

Time (per yr)

0.63 (0.16, 1.09)

0.009

Number of medications (per medication)

CI, conﬁdence interval; CTX, Cytoxan (cyclophosphamide); eGFR, estimated glomerular
ﬁltration rate; FSGS, focal segmental glomerular sclerosis; IgAN, IgA nephropathy; IgAV,
IgA vasculitis; MCD, minimal change disease; MN, membranous nephropathy; Ref,
referent; SES, socioeconomic status.
For each domain, scores have been transformed so higher scores indicate better
health-related quality of life. Other tested covariates that were tested but not signiﬁcant
in any of the ﬁnal models included race, disease duration, socioeconomic status,
diagnosis, ethnicity, hospitalizations, short stature, urine protein–creatinine ratio, hemoglobin, immunosuppression exposure, steroid dose in the past 30 days, and steroid
response pattern.

collecting longitudinal data, this study details how
HRQOL in this population changes over time. Disease
activity and key PRO, particularly edema, have
important associations with HRQOL. In CureGN,
HRQOL improved in association with reductions in
edema and number of symptoms.
Kidney International Reports (2020) 5, 1679–1689
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HRQOL improved over time in nearly all domains,
with the greatest improvement seen in fatigue. This
was true for both children and adults. The inﬂuence of
time in adjusted models was small and changes in
disease activity were stronger predictors of HRQOL.
Notably, edema was the strongest predictor of HRQOL
scores and change in within-patient edema status from
one visit to the next was associated with change in
HRQOL across all domains. This is consistent with
cross-sectional analyses suggesting edema as a strong
predictor of HRQOL in this population.16–18 Although
not surprising given how profoundly edema can affect
individuals with these diseases, these longitudinal results add to prior cross-sectional work by demonstrating that changes in edema for an individual patient
over time are associated with change in HRQOL.
Though proteinuria and serum albumin were associated
with all HRQOL measures in unadjusted analyses, in
the ﬁnal multivariable model, proteinuria failed to be
an independent predictor of HRQOL and albumin was
signiﬁcant in only 4 of 7 domains. The only domain in
which no signiﬁcant improvement occurred over time
was adult mental health, but many improvements were
relatively modest.
The number of symptoms was predictive of scores
on all HRQOL measures, which reinforces the importance of patient experience—from a disease or its
treatment—for HRQOL. The fact that both edema and
number of symptoms were stronger predictors of
HRQOL than laboratory markers is particularly meaningful. In clinical practice, these lab-based markers of
disease activity—proteinuria, serum albumin, and
eGFR—are often given more attention than the more
patient-centered metrics of edema or symptom reporting. Our ﬁndings underscore the importance of these
PROs as meaningful for individuals with primary
glomerular disease—in practice as well as in research.
Other variables that were longitudinally associated
with worse HRQOL in various domains included
number of comorbidities, obesity, female sex, lower
SES, and lower serum albumin. The relationship between HRQOL scores and variables such as sex,
obesity, SES, and comorbidity has been reported previously in other settings.19 For these primary glomerular diseases, we were interested in whether HRQOL
was responsive to changes in disease activity, as
measured by edema, proteinuria, serum albumin, and
eGFR. In the ﬁnal model, only eGFR was signiﬁcant in
predicting fatigue in adults and children and physical
health in adults. Diagnosis was independently associated with 2 domains of HRQOL, sleep impairment and
mental health, in adults. Speciﬁcally, HRQOL scores
were best in IgAV, followed by MN, IgAN, FSGS, and
MCD. There was no relationship between diagnosis and
1685
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Figure 3. Linear mixed effects models of change in patient-reported outcomes since last visit by edema. CI, conﬁdence interval; PROMIS,
Patient-Reported Outcomes Measurement Information System.

HRQOL in children. The lack of association between
diagnosis and HRQOL in most domains suggests that
among these glomerular diseases, individual patient
factors and clinical markers are more important determinants of HRQOL than the speciﬁc disease. IST was
not retained in any of the ﬁnal models as an independent predictor of HRQOL. This may be due at least in
part to the opposing effects on HRQOL by IST. Though
IST can have signiﬁcant side effects that adversely
affect HRQOL, it can also improve HRQOL through
decreasing the symptoms and disease effects.
The effect sizes found in this study were relatively
modest. Most of the statistically signiﬁcant differences
reported here were smaller than the PROMIS minimally important difference of j3.0j. It is important to
note, however, that these differences are for the
group, and it is likely that a substantial number of
individuals achieved this level of change. Nonetheless, these attenuated ﬁndings at the group level are
surprising because clinical experience and prior
studies suggest primary glomerular diseases can have
a profound impact on one’s quality of life,6,7 and we
suspect that this may reﬂect limited sensitivity of the
PRO measure used. Decreased responsiveness of the
instrument may also explain the lack of association we
found for some putative determinants of HRQOL,
1686

such as proteinuria, eGFR, diagnosis, and IST.
Disease-speciﬁc PRO instruments are more responsive
to disease status changes than generic instruments;
however, no validated disease-speciﬁc PRO instruments existed for these glomerular diseases when
data collection for CureGN began. A previous study
of 127 children with nephrotic syndrome did not
identify statistically signiﬁcant trends between
changes in disease activity and changes in PROMIS
scores; however, changes did correlate with other selfreported global assessments of change.20 Our study
highlights the importance of measuring PROs but also
shows that developing more responsive instruments
for patients with glomerular disease is critical to the
utility of PROs for patients, providers, and researchers alike.
This study was limited by lack of a validated PRO
instrument, which should include input from the
target population, generally elicited via qualitative
methods.21,22 The domains included in the CureGN
PRO assessment were selected based on available data
and knowledge of the diseases at the inception of this
study, but no such data on patient experience in this
population had been published. Research since that
time has corroborated the importance of the domains
included here,23 but we suspect that not all the
Kidney International Reports (2020) 5, 1679–1689
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domains important to the experience of these diseases
are captured by our assessment. Another limitation of
this study is that some domains are composed of a
single item (anxiety in children and adults, sleep impairments in adults) and thus provide less precision.
Choice of domains was informed by prior work in pediatric nephrotic syndrome, and little published data
was available to guide choice of domains in adult
nephrotic syndrome.17,18 Additionally, it is possible
that the temporal improvements seen in this cohort are
attributable to enrollment in a clinical research study,
which may limit generalization beyond CureGN participants. Alternatively, temporal improvements could
be inﬂuenced by incomplete follow-up. Although we
did not observe baseline differences in HRQOL among
those with and without longitudinal HRQOL data, it is
possible that participants who withdrew early, and
were thus absent from this analysis, also had a decrease
in HRQOL. Finally, although we controlled for disease
activity and severity (edema, proteinuria, albumin,
eGFR, hemoglobin, and health care utilization), disease
severity may not be adequately reﬂected by these
covariates.
In conclusion, HRQOL scores improved over time in
both children and adults with primary glomerular
diseases, with the greatest improvements in fatigue.
Edema was the strongest longitudinal predictor of
poorer HRQOL, highlighting the importance of
addressing this symptom. Although this is the largest
study of HRQOL in patients with glomerular diseases to
date, the impact of these diseases on patient experience
is likely to be incompletely captured here, and welldeveloped validated measures are needed. Direct
input from patients in such scientiﬁc inquiry will
greatly improve knowledge that meaningfully impacts
clinical care.
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